Navigation Links
Portable device effective in zapping away migraine pain
Date:6/25/2008

COLUMBUS, Ohio A novel electronic device designed to "zap" away migraine pain before it starts has proven to be the next form of relief for those suffering from the debilitating disease, according to a study conducted at The Ohio State University Medical Center.

Results of the study, to be presented Friday (6/27) at the annual American Headache Society meeting in Boston, found that the experimental device is safe and effective in eliminating headaches when administered during the onset of the migraine.

With one in eight Americans suffering from chronic migraines, Dr. Yousef Mohammad, a neurologist and principal investigator of the study at Ohio State's Medical Center, says the study's results are promising given that only 50 to 60 percent of migraine patients respond to traditional migraine drug treatments.

The noninvasive transcranial magnetic stimulator (TMS) device interrupts the aura phase of the migraine, often described as electrical storms in the brain, before they lead to headaches. Migraine sufferers often describe "seeing" showers of shooting stars, zigzagging lines and flashing lights, and experiencing loss of vision, weakness, tingling or confusion, followed by intense throbbing head pain, nausea and vomiting.

Previous studies, conducted at Ohio State, using a heavy and bulky TMS device, reduced headache pain. To expedite treatment at home, a portable hand-held device was developed and tested.

"Stimulation with magnetic pulses from the portable TMS device proved effective for the migraine patients," said Mohammad. "Because of the lack of adverse events in this trial and the established safety of the TMS device, this is a promising treatment for migraines with aura. This sets the stage for future studies in migraines without aura."

The TMS device sends a strong electric current through a metal coil, which creates an intense magnetic field for about one millisecond. This magnetic pulse, when held against a person's head, creates an electric current in the neurons of the brain, interrupting the aura before it results in a throbbing headache.

"The device's pulses are painless and safe," Mohammad said. "Since almost all migraine drugs have some side effects, and patients are prone to addiction from narcotics, or developing headaches from frequent use of over-the-counter medication, the TMS device holds great promise for migraine sufferers."

Of the 164 patients involved in the multi-center, randomized clinical trial receiving TMS treatment, 39 percent were pain free at the two-hour post-treatment point, compared to 22 percent in the group receiving "sham" pulses. There were no differences reported related to adverse reactions between the two groups.

It was previously believed that migraine headaches start with vascular constriction, which results in an aura, followed by vascular dilation that will lead to a throbbing headache. However, in the late 1990's it was suggested that neuronal electrical hyperexcitablility resulted in a throbbing headache. This new understanding of the migraine mechanism assisted in the development of the TMS device.


'/>"/>

Contact: Sherri L. Kirk
Sherri.Kirk@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Officeinacar Introduces Deskinacar - The Truly Portable Car Desk: the Lightweight Solution to a Businesspersons Travel Office Needs
2. AmeriCares Purchases BLU-MED Portable Hospital for China Earthquake Relief
3. Cantimer, Inc. Awarded $996,000 Contract from U.S. Government to Develop Portable, Real-Time and Non-Invasive Hydration Measurement and Monitoring System for Use by Firefighters
4. Dawning Technologies, Inc. Releases JavaLin/PDI Portable Device Interface
5. Pilot study reinforces use of portable anteroom HEPA filtration
6. Cardiac Science Corporation Selects Colubris Networks Wireless Solution for its Portable Electrocardiograph
7. Portable Computer Devices Can Aid Exercise Programs
8. OxySure(R) Systems, Inc. Named to 2008 Worlds Best Technologies (WBT) List For its Unique, Safe and Easy to Use Portable Emergency Oxygen Generator, Which Provides Medical Oxygen Without the Need for Compressed Tanks
9. Lab on a chip developed at University of Alberta for cheap, portable medical tests
10. Vermont Requires Reporting of NQF Serious Reportable Events
11. San Diegos SeQual Technologies Loans 35 Portable Oxygen Units to Evacuees at Qualcomm Stadium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , ... May 03, 2016 , ... ... announced that it has been honored as one of the nation’s most accomplished ... InformationWeek Elite 100. Horizon received the recognition for technology achievements that have enabled ...
(Date:5/3/2016)... ... May 03, 2016 , ... BioPlus Specialty Pharmacy ... at the 2016 Asembia Specialty Pharmacy Summit held May 2-6, 2016 at the ... health care conference for the specialty pharmacy industry, with thousands of pharmacy providers, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Empyrean Benefit Solutions, Inc., the ... service center in La Vergne, Tennessee, near Nashville. The new center will complement ... Empyrean client services. , “Our Nashville-area center allows us to achieve several goals,” ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Park Cities ... live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, ... Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... one of Canada’s top Information and Communication Technology (ICT) companies in the annual ... Multinational ICT companies operating in Canada, as ranked by revenue. , “We ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
(Date:4/29/2016)... , April 29, 2016 ... H1 2016" market research report that provides an ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology ... appointment of Dr. Alfredo Zurlo as Chief ... with many years clinical experience and a proven track ... role was at Mologen AG where he was Chief ... Dr. Zurlo held various positions at F Hoffmann La ...
Breaking Medicine Technology: